Intuitive Surgical, Inc. (ETR:IUI1)
Germany · Delayed Price · Currency is EUR | Market Cap | 137.33B -3.9% |
| Revenue (ttm) | 10.20B +20.5% |
| Net Income | 2.60B +7.7% |
| EPS | 7.37 +9.5% |
| Shares Out | n/a |
| PE Ratio | 53.19 |
| Forward PE | 36.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 652 |
| Open | 380.85 |
| Previous Close | 384.45 |
| Day's Range | 375.90 - 393.65 |
| 52-Week Range | 290.45 - 516.10 |
| Beta | 1.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 20, 2026 |
About Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling,... [Read more]
Financial Performance
In 2025, Intuitive Surgical's revenue was $10.06 billion, an increase of 20.51% compared to the previous year's $8.35 billion. Earnings were $2.86 billion, an increase of 22.97%.
Financial numbers in USD Financial StatementsNews
Intuitive Surgical price target raised to $503 from $473 at Leerink
Leerink analyst Mike Kratky raised the firm’s price target on Intuitive Surgical (ISRG) to $503 from $473 and keeps an Outperform rating on the shares. The firm believes post-market volatility…
Intuitive Surgical price target lowered to $480 from $483 at Raymond James
Raymond James lowered the firm’s price target on Intuitive Surgical (ISRG) to $480 from $483 and keeps an Outperform rating on the shares. Despite slowing U.S. procedure growth, Intuitive Surgical’s…
Intuitive Surgical price target lowered to $550 from $575 at RBC Capital
RBC Capital lowered the firm’s price target on Intuitive Surgical (ISRG) to $550 from $575 and keeps an Outperform rating on the shares. The stock fell after Q3 results and…
Intuitive Surgical price target raised to $475 from $450 at JPMorgan
JPMorgan raised the firm’s price target on Intuitive Surgical (ISRG) to $475 from $450 and keeps an Overweight rating on the shares. The firm views the Q3 earnings report as…
Intuitive Surgical price target lowered to $400 from $415 at Mizuho
Mizuho lowered the firm’s price target on Intuitive Surgical (ISRG) to $400 from $415 and keeps a Neutral rating on the shares following the Q3 report. The firm cites persisting…
Intuitive Surgical price target raised to $550 from $513 at Baird
Baird raised the firm’s price target on Intuitive Surgical (ISRG) to $550 from $513 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results…
Intuitive Surgical price target lowered to $486 from $487 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Intuitive Surgical (ISRG) to $486 from $487 and keeps an Overweight rating on the shares. The firm notes the…
Intuitive Surgical upgraded to Buy from Hold at Erste Group
Erste Group upgraded Intuitive Surgical (ISRG) to Buy from Hold. The growth trajectory for revenue and profits is continuing and the firm expects the stock to post further gains in…
Intuitive Surgical price target raised to $500 from $485 at Barclays
Barclays raised the firm’s price target on Intuitive Surgical (ISRG) to $500 from $485 and keeps an Overweight rating on the shares. The company’s Q3 results “delivered on just about…
Intuitive Surgical says in China, the operating environment remains challenging
Says continued to see increasing segmentation across our customer base. Says as of Q3, nearly 4,000 international customers have a Da Vinci program, and nearly 25% operate two or more…
Intuitive Surgical Stock Slides Despite Earnings Beat as Company Discloses Settlement
Intuitive Surgical beat quarterly estimates but disclosed an antitrust settlement and narrowed its procedure-growth forecast.
Intuitive Surgical announces $450M antitrust litigation settlement agreement
Following a mediation in the “In re: da Vinci Surgical Robot Antitrust Litigation” class action, the company reached written agreement, without any admission of liability or wrongdoing, to settle the…
Intuitive Surgical Earnings Call Transcript: Q3 2026
Q3 revenue rose 22% and procedures grew 15%, supported by broad system placements and growth across da Vinci and Ion. FY2026 da Vinci procedure growth guidance narrowed to 14%-15%; upcoming pricing actions are expected to reduce I&A revenue per procedure 3%-5% at constant mix once fully implemented.
Intuitive Surgical Earnings release: Q3 2026
Intuitive Surgical released its Q3 2026 earnings on October 20, 2026, summarizing the period's financial results.
Intuitive Surgical Quarterly report: Q3 2026
Intuitive Surgical has published its Q3 2026 quarterly earnings report on October 20, 2026.
Intuitive Surgical Slides: Q3 2026
Intuitive Surgical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 20, 2026.
Intuitive Surgical reports Q3 EPS $3.00, consensus $2.64
Reports Q3 revenue $3.05B, consensus $2.91B. Worldwide procedures grew approximately 15% compared with the third quarter of 2025. Da Vinci procedures grew approximately 14%, and Ion procedures grew ap...
Intuitive Surgical narrows FY26 da Vinci procedure growth view to 14%-15%
Previous view was 13.5%-15.5%. Raises FY26 gross profit margin view to 68.7%-69.3% from 68%-69%. Backs FY26 operating expense growth view 11%-13%. The company said, “The range for expected non-GAAP gr...
Intuitive Announces Third Quarter Earnings
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today ...
Intuitive Surgical price target raised to $415 from $400 at Mizuho
Mizuho raised the firm’s price target on Intuitive Surgical (ISRG) to $415 from $400 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices…
Intuitive Surgical price target lowered to $454 from $469 at BTIG
BTIG lowered the firm’s price target on Intuitive Surgical (ISRG) to $454 from $469 and keeps a Buy rating on the shares as part of a broader research note previewing…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Intuitive Surgical Transcript: Wells Fargo 21st Annual Healthcare Conference
Global procedure growth remains a priority, with innovation and new programs like Extended Use Instruments aimed at stimulating growth, especially in cost-sensitive markets. Capital equipment placements are strong, competition is intensifying, and AI-driven digital offerings are gaining traction. Financial performance is robust, exceeding long-term averages.
New meta-analysis shows statistically significant improvements in patient outcomes associated with da Vinci surgery versus laparoscopic and open surgery across 13 common benign conditions
Largest comparative meta-analysis of its kind found da Vinci robotic-assisted surgery was associated with shorter hospital stays and a faster return to work compared with laparoscopic and open surgery...